Charles Nichols

Scientific Founder at Eleusis

Charles is a Professor of Pharmacology at LSU Health Sciences Center in New Orleans, and has been researching psychedelics for nearly 25 years. He received his PhD at Carnegie Mellon University, where his research focused on molecular and genetic aspects of retinal development. He then moved to Vanderbilt University School of Medicine for his postdoctoral training in serotonin neuropharmacology.

Charles has made groundbreaking discoveries with respect to the effects of serotonin 5-HT2A receptor agonists in the central nervous system at the cellular, molecular, and genetic level that have informed on fundamental brain processes related to normal cognitive function and psychiatric disorders. Charles discovered that psychedelics have powerful anti-inflammatory effects mediated by the 5-HT2A receptor through functionally selective processes. A major component of his current research program is dedicated to elucidating the molecular pathways and mechanisms underlying the anti-inflammatory effects of serotonin 5-HT2A receptor agonists and enabling the translation of these findings into clinically relevant therapeutics.


  • Scientific Founder

    Current role

  • Scientific Founder & Sponsored Researcher